Literature DB >> 17314366

Saccharomyces cerevisiae strain 905 reduces the translocation of Salmonella enterica serotype Typhimurium and stimulates the immune system in gnotobiotic and conventional mice.

Flaviano S Martins1,2,3, Ana Cristina P Rodrigues4, Fabiana C P Tiago3, Francisco J Penna2, Carlos A Rosa3, Rosa M E Arantes5, Regina M D Nardi3, Maria J Neves1, Jacques R Nicoli3.   

Abstract

Previous results in the laboratory of the authors showed that Saccharomyces cerevisiae strain 905, isolated during 'cachaça' production, was able to colonize and survive in the gastrointestinal tract of germ-free and conventional mice, and to protect these animals against oral challenge with Salmonella enterica serotype Typhimurium or Clostridium difficile. In the present work, the effects of S. cerevisiae 905 on the translocation of Salm. Typhimurium (mesenteric lymph nodes, Peyer's patches, spleen, liver) as well as on the immune system (number of Küpffer cells, immunoglobulin production, clearance of Escherichia coli B41) were evaluated in gnotobiotic and/or conventional mice. The treatment with the yeast reduced significantly the translocation of Salm. Typhimurium to liver in gnotobiotic animals and to all the organs tested in conventional mice. The number of Küpffer cells per 100 hepatocytes in liver was significantly higher (P<0.05) in yeast mono-associated mice (52.9+/-15.7) than in germ-free controls (38.1+/-9.0). Probably as a consequence, clearance of E. coli B41 from the bloodstream was more efficient in yeast mono-associated animals when compared to germ-free mice. Higher levels (P<0.05) of secretory IgA in intestinal content and of IgA and IgM in serum were observed in yeast mono-associated mice when compared to germ-free group. Concluding, the protection against pathogenic bacteria observed in a previous study was probably due to a modulation of both local and systemic immunity of mice treated with S. cerevisiae 905.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17314366     DOI: 10.1099/jmm.0.46525-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  18 in total

1.  Use of artificial digestive systems to investigate the biopharmaceutical factors influencing the survival of probiotic yeast during gastrointestinal transit in humans.

Authors:  Stéphanie Blanquet-Diot; Sylvain Denis; Sandrine Chalancon; Fehd Chaira; Jean-Michel Cardot; Monique Alric
Journal:  Pharm Res       Date:  2011-11-09       Impact factor: 4.200

2.  Probiotic yeasts: anti-inflammatory potential of various non-pathogenic strains in experimental colitis in mice.

Authors:  Benoît Foligné; Joëlle Dewulf; Pascal Vandekerckove; Georges Pignède; Bruno Pot
Journal:  World J Gastroenterol       Date:  2010-05-07       Impact factor: 5.742

3.  Novel insights in genetic transformation of the probiotic yeast Saccharomyces boulardii.

Authors:  Bruno Douradinha; Viviane C B Reis; Matthew B Rogers; Fernando A G Torres; Jared D Evans; Ernesto T A Marques
Journal:  Bioengineered       Date:  2013-09-05       Impact factor: 3.269

4.  Protection against increased intestinal permeability and bacterial translocation induced by intestinal obstruction in mice treated with viable and heat-killed Saccharomyces boulardii.

Authors:  Simone V Generoso; Mirelle L Viana; Rosana G Santos; Rosa M E Arantes; Flaviano S Martins; Jacques R Nicoli; José A N Machado; Maria Isabel T D Correia; Valbert N Cardoso
Journal:  Eur J Nutr       Date:  2010-10-10       Impact factor: 5.614

5.  Evaluation of a Functional Craft Wheat Beer Fermented with Saccharomyces cerevisiae UFMG A-905 to treat Salmonella Typhimurium infection in mice.

Authors:  Samantha R M Oliveira; Lara L Campos; Maisa N S Amaral; Bruno Galotti; Mayra F Ricci; Katia D Vital; Ramon O Souza; Ana Paula T Uetanabaro; Mateus S Junqueira; Andreia M Silva; Simone O A Fernandes; Valbert N Cardoso; Jacques R Nicoli; Flaviano S Martins
Journal:  Probiotics Antimicrob Proteins       Date:  2022-07-30       Impact factor: 5.265

6.  Interaction of Saccharomyces boulardii with Salmonella enterica serovar Typhimurium protects mice and modifies T84 cell response to the infection.

Authors:  Flaviano S Martins; Guillaume Dalmasso; Rosa M E Arantes; Anne Doye; Emmanuel Lemichez; Patricia Lagadec; Veronique Imbert; Jean-François Peyron; Patrick Rampal; Jacques R Nicoli; Dorota Czerucka
Journal:  PLoS One       Date:  2010-01-27       Impact factor: 3.240

7.  Gut bacteria drive Kupffer cell expansion via MAMP-mediated ICAM-1 induction on sinusoidal endothelium and influence preservation-reperfusion injury after orthotopic liver transplantation.

Authors:  Natasha Corbitt; Shoko Kimura; Kumiko Isse; Susan Specht; Lisa Chedwick; Brian R Rosborough; John G Lunz; Noriko Murase; Shinichiro Yokota; Anthony J Demetris
Journal:  Am J Pathol       Date:  2012-11-14       Impact factor: 4.307

Review 8.  Probiotic products in Canada with clinical evidence: what can gastroenterologists recommend?

Authors:  G Reid; K Anukam; T Koyama
Journal:  Can J Gastroenterol       Date:  2008-02       Impact factor: 3.522

9.  In Vitro and In Vivo Evaluation of the Probiotic Potential of Antarctic Yeasts.

Authors:  Joana O P A Coutinho; Taynara S Peixoto; Graciéle C A de Menezes; Camila R Carvalho; Mayara B Ogaki; Eldon C Q Gomes; Carlos A Rosa; Luiz H Rosa; Rosa M E Arantes; Jacques R Nicoli; Fabiana C P Tiago; Flaviano S Martins
Journal:  Probiotics Antimicrob Proteins       Date:  2021-03-23       Impact factor: 4.609

10.  Antarctic Strain of Rhodotorula mucilaginosa UFMGCB 18,377 Attenuates Mucositis Induced by 5-Fluorouracil in Mice.

Authors:  Joana O P A Coutinho; Mônica F Quintanilha; Marina R A Campos; Enio Ferreira; Graciéle C A de Menezes; Luiz H Rosa; Carlos A Rosa; Katia D Vital; Simone O A Fernandes; Valbert N Cardoso; Jacques R Nicoli; Fabiana C P Tiago; Flaviano S Martins
Journal:  Probiotics Antimicrob Proteins       Date:  2021-07-13       Impact factor: 5.265

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.